REGOLI, Domenico
 Distribuzione geografica
Continente #
NA - Nord America 12.603
AS - Asia 5.607
EU - Europa 3.438
SA - Sud America 765
AF - Africa 112
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 22.538
Nazione #
US - Stati Uniti d'America 12.312
SG - Singapore 2.144
CN - Cina 1.478
DE - Germania 859
VN - Vietnam 598
BR - Brasile 581
UA - Ucraina 577
IT - Italia 484
GB - Regno Unito 413
HK - Hong Kong 404
TR - Turchia 367
FI - Finlandia 346
FR - Francia 207
CA - Canada 185
RU - Federazione Russa 146
BD - Bangladesh 144
SE - Svezia 137
JP - Giappone 115
IN - India 113
MX - Messico 66
AR - Argentina 57
PL - Polonia 51
ZA - Sudafrica 47
IQ - Iraq 43
BE - Belgio 42
NL - Olanda 40
ES - Italia 36
PK - Pakistan 36
LT - Lituania 30
CO - Colombia 29
ID - Indonesia 29
EC - Ecuador 28
UZ - Uzbekistan 21
VE - Venezuela 18
CL - Cile 16
MA - Marocco 16
MY - Malesia 16
AE - Emirati Arabi Uniti 15
PH - Filippine 13
SA - Arabia Saudita 13
EG - Egitto 11
PE - Perù 11
PY - Paraguay 10
TN - Tunisia 10
AL - Albania 9
AU - Australia 9
UY - Uruguay 9
AT - Austria 8
CZ - Repubblica Ceca 8
BG - Bulgaria 7
IR - Iran 7
JM - Giamaica 7
JO - Giordania 7
IL - Israele 6
KE - Kenya 6
LB - Libano 6
SN - Senegal 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
NP - Nepal 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
CH - Svizzera 4
ET - Etiopia 4
HN - Honduras 4
HR - Croazia 4
PA - Panama 4
BH - Bahrain 3
BO - Bolivia 3
DK - Danimarca 3
HU - Ungheria 3
KZ - Kazakistan 3
NI - Nicaragua 3
PT - Portogallo 3
RO - Romania 3
RS - Serbia 3
SR - Suriname 3
AZ - Azerbaigian 2
BJ - Benin 2
CY - Cipro 2
DZ - Algeria 2
EU - Europa 2
GR - Grecia 2
IE - Irlanda 2
KH - Cambogia 2
KR - Corea 2
MN - Mongolia 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AI - Anguilla 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BY - Bielorussia 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
Totale 22.521
Città #
Ashburn 1.512
Singapore 1.419
Fairfield 1.109
Woodbridge 1.076
San Jose 691
Houston 673
Jacksonville 616
Ann Arbor 559
Chandler 519
Beijing 480
Santa Clara 479
Seattle 421
Hong Kong 400
Wilmington 392
Cambridge 352
Munich 342
Dallas 281
Los Angeles 268
New York 265
Ho Chi Minh City 199
Izmir 193
Nanjing 178
Helsinki 152
Milan 141
Hanoi 132
Princeton 119
San Diego 113
Tokyo 111
Boardman 100
Lauterbourg 97
Orem 87
Denver 79
Shanghai 78
Brooklyn 72
Turku 71
Montreal 63
São Paulo 63
London 60
Atlanta 58
Nanchang 58
Dearborn 57
Phoenix 51
Shenyang 51
Toronto 50
Frankfurt am Main 46
Buffalo 45
San Francisco 45
Council Bluffs 44
Falls Church 44
Chicago 41
Brussels 40
Warsaw 39
Boston 38
Mexico City 35
Bremen 33
Falkenstein 33
Hefei 33
Hebei 32
Tianjin 32
Ferrara 31
Johannesburg 30
Auburn Hills 29
Jiaxing 29
Changsha 28
Da Nang 27
Jinan 27
Mountain View 27
San Mateo 27
Manchester 26
Philadelphia 26
Chennai 23
Mcallen 22
Moscow 22
Norwalk 22
Stockholm 21
Haiphong 20
Redwood City 20
Rio de Janeiro 20
Addison 19
Poplar 19
Tashkent 19
The Dalles 19
Kunming 18
Zhengzhou 18
Baghdad 17
Montréal 17
Amsterdam 16
Mumbai 16
Bexley 15
Curitiba 14
Dhaka 13
Guangzhou 13
Hải Dương 13
Lahore 13
Belo Horizonte 12
Indiana 12
Ningbo 12
Tappahannock 12
Ankara 11
Pittsburgh 11
Totale 15.673
Nome #
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor 1.248
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 394
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 338
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 319
A new selective antagonist of the nociceptin receptor 274
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 272
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 270
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 269
Effects of vasoactive agents in healthy and diseased human saphenous veins 268
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 266
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 261
A new ligand for the urotensin II receptor 257
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 244
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 244
Ala scan analogues of HOE 140. Synthesis and biological activities 240
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 237
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 233
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 232
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 228
Autoradiographic analysis of rat brain kinin B-1 and B-2 receptors: Normal distribution and alterations induced by epilepsy 225
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 224
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 223
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 222
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 222
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 221
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 220
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 218
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 218
Pharmacological characterisation of novel kinin B2 receptor ligands 217
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 216
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 215
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 212
B1 and B2 kinin receptors in various species 212
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 209
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 208
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 206
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 205
Pharmacological characterization of nociceptin receptor: an in vitro study 205
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 204
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 202
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 202
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 201
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 201
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 200
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 199
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 198
Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy 197
Structure-activity study at positions 3 and 4 of human neuropeptide S. 196
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 196
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist 194
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 193
Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors) 189
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 187
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 186
Characterization of the human vascular kinin B2 receptor by binding assays. 182
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 181
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 179
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 178
Nociceptin/orphanin FQ receptor ligands 177
Structure-activity relationship study on human urotensin II 177
Angiotensin II-induced increase of T-type Ca2+ current and decrease of L-type Ca2+ current in heart cells 177
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 175
Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice 174
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 172
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 172
ANTAGONISTI DEL RECETTORE UT E LORO USI TERAPEUTICI 171
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 171
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 170
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 169
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 167
Pharmacology of nociceptin and its receptor: a novel therapeutic target 167
Characterization of endothelin receptors in the human umbilical artery and vein 165
Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats 163
In vitro pharmacological profile of peptide III-BTD: A novel ligand for nociceptin/orphanin FQ and opioid receptors 162
Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure activity relationships 161
Pharmacology of the Kallikrein-Kinin system 159
The mouse vas deferens: A pharmacological preparation sensitive to nociceptin 159
Effects of intrathecal nocistatin on the flexor reflex and its interaction with orphanin FQ nociceptin 158
In vitro characterization of FR 190997, the first non peptide B2 receptor agonist receptor binding and bioassay in the human umbilical vein 157
Angiotensin II induced increase in frequency of cytosolic and nuclear calcium waves of heart cells via activation of AT(1) and AT(2) receptors 157
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor 156
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor 156
Receptors for kinins in the human isolated umbilical vein 154
Effects of Ro 64-6198 it nociceptin/orphanin FQ-sensitive isolated tissues 153
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors 151
Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation 145
Further studies on nociceptin related peptides: discovery of new molecules with antagonist activity on the nociceptin receptor 144
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study 144
Receptor binding profile of novel nociceptin/orphanin FQ receptor ligands in mouse brain membranes. 142
Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities 140
Further studies on nociceptin/orphanin FQ related peptides: discovery of a new chemical template with antagonist activity on the OP4 receptor. 135
Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test 135
Pharmacological characterization of the nociceptin receptors in the mouse: receptor binding, bioassay and behavioral studies 132
Pharmacology of [tyr1]nociceptin analogs: receptor binding and bioassay studies 132
Expression and biological activity of B1 bradykinin receptors in two experimental models of epilepsy 128
Identificazione di un antagonista del recettore UT 128
Characterization of the human vascular kinin B2 receptor by binding assays 128
Pharmacological characterisation of [(pX)Phe(4)]nociceptin(1-13)amide analogues - 1. In vitro studies 127
Identificazione di un agonista parziale del recettore per il neuropeptide S 124
MEN 11270, a novel selective constrained peptide antagonist with high affinity at the human B-2 kinin receptor 121
Totale 20.512
Categoria #
all - tutte 94.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.014


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.308 44 137 96 98 87 56 73 72 57 94 123 371
2022/20231.332 125 50 62 168 224 176 112 100 196 7 68 44
2023/2024631 76 78 37 16 39 133 21 42 13 12 14 150
2024/20252.785 54 51 206 106 337 315 133 177 397 244 405 360
2025/20267.580 827 316 632 996 1.142 479 896 341 703 783 310 155
2026/20271.241 1.241 0 0 0 0 0 0 0 0 0 0 0
Totale 22.643